Summer Sale
50% off Premium Yearly
NYSE:RVTY
Revvity (RVTY)
Financials 
Technical Analysis 
Jun 11, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
Revvity (RVTY-N) has recently made significant strides in the life sciences sector, especially following a period of stagnation. The company unveiled impressive financial results last October, which prompted an upward revision of its full-year earnings forecast, indicating a turnaround in its business performance. Experts note that RVTY-N trades at a price-to-earnings ratio of 21, making it one of the most attractively priced stocks in its sector, suggesting that it may present a good opportunity for investors. Given its recent recovery, combined with a favorable valuation compared to its peers, analysts are optimistic about the company's growth prospects moving forward. Overall, Revvity seems well-positioned for continued improvement and potentially stronger returns for its shareholders in the coming months.
- «
- ‹
- 1
- ›
- »
Revvity (RVTY) Frequently Asked Questions
What is Revvity stock symbol?
Revvity is a American stock, trading under the symbol RVTY (previously RVTY-N on Stockchase) on the New York Stock Exchange (RVTY). It is usually referred to as NYSE:RVTY or RVTY
Is Revvity a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on RVTY (previously RVTY-N on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Revvity.
Is Revvity a good investment or a top pick?
Revvity was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Revvity.
Why is Revvity stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Revvity.
Is Revvity worth watching?
Revvity is covered by Stockchase experts and is worth watching.
What is Revvity stock price?
On 2026-06-12, Revvity (RVTY) stock closed at a price of $99.66.
A life sciences company. After years of going nowhere, they finally posted good numbers last October and raised their full-year earnings forecast. Trades at 21x PE, the cheapest in the sector.